Antiplatelet medications in the secondary prevention of ischemic stroke

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


It is difficult to make general statements regarding choices in the medical management of patients with IS given its multiple mechanisms and individual patient variations. It is exceedingly important to manage all vascular risk factors in each patient, especially hypertension. Managing risk factors is as important as, or perhaps more important than, deciding on a prevention medication. Based on the previous discussion, I present my recommendations for antiplatelet secondary prevention of noncardioembolic IS.